Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2036-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous
CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma